Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Michael T. Constantino net worth and biography

Michael Constantino Biography and Net Worth

Director of Humacyte

Mr. Constantino is a retired Ernst & Young LLP assurance partner who served in the Research Triangle Park region of North Carolina for over 30 years. Mr. Constantino holds a B.A. in both Accounting and Business Management from NC State University and is a North Carolina Certified Public Accountant, or CPA. Mr. Constantino is serves as Chair of Humacyte’s Audit Committee.

What is Michael T. Constantino's net worth?: The estimated net worth of Michael T. Constantino is at least $78,648.00 as of December 4th, 2024. Mr. Constantino owns 16,950 shares of Humacyte stock worth more than $78,648 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Constantino may own. Learn More about Michael T. Constantino's net worth.
How do I contact Michael T. Constantino?: The corporate mailing address for Mr. Constantino and other Humacyte executives is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. Humacyte can also be reached via phone at 919-313-9633 and via email at [email protected]. Learn More on Michael T. Constantino's contact information.
Has Michael T. Constantino been buying or selling shares of Humacyte?: During the past quarter, Michael T. Constantino has bought $20,194.00 of Humacyte stock. Most recently, on Wednesday, December 4th, Michael T. Constantino bought 4,600 shares of Humacyte stock. The stock was acquired at an average cost of $4.39 per share, with a total value of $20,194.00. Following the completion of the transaction, the director now directly owns 16,950 shares of the company's stock, valued at $74,410.50. Learn More on Michael T. Constantino's trading history.
Who are Humacyte's active insiders?: Humacyte's insider roster includes Michael Constantino (Director), Brady Dougan (Director), and Laura Niklason (CEO). Learn More on Humacyte's active insiders.
Are insiders buying or selling shares of Humacyte?: During the last twelve months, Humacyte insiders bought shares 4 times. They purchased a total of 59,012 shares worth more than $389,301.20. During the last twelve months, insiders at the sold shares 13 times. They sold a total of 4,212,973 shares worth more than $25,940,916.90. The most recent insider tranaction occured on December, 4th when Director Michael T Constantino bought 4,600 shares worth more than $20,194.00. Insiders at Humacyte own 11.2% of the company. Learn More about insider trades at Humacyte.
Information on this page was last updated on 12/4/2024.

Michael T. Constantino Insider Trading History at Humacyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/4/2024	Buy	4,600	$4.39	$20,194.00	16,950
5/23/2022	Buy	2,000	$4.83	$9,660.00	4,500
11/22/2021	Buy	2,500	$10.79	$26,975.00

Michael T. Constantino Buying and Selling Activity at Humacyte

Humacyte Company Overview

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Today's Range

Now: $4.64

$4.45

$6.77

50 Day Range

MA: $4.83

$3.46

$5.82

2 Week Range

Now: $4.64

$2.48

$9.97

Volume

75,231,266 shs

Average Volume

2,735,148 shs

Market Capitalization

$583.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

First JFK… next Elon?

From Porter & Company | Ad